<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10059">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02091505</url>
  </required_header>
  <id_info>
    <org_study_id>MKONDO-CRVO</org_study_id>
    <nct_id>NCT02091505</nct_id>
  </id_info>
  <brief_title>Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO</brief_title>
  <acronym>CRVO</acronym>
  <official_title>Predictive Factors of Treatment Outcome After Intravitreal Injection of Lucentis (Ranibizumab) in Eyes With Macular Edema Associated With Central Retinal Vein Occlusion (CRVO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mie University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mie University</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have shown that intravitreal injection of anti-VEGF agent, Lucentis
      (Ranibizumab) is effective for macular edema associated with central retinal vein occlusion
      (CRVO). However, there is little information on whether there are any predictive factors of
      treatment outcome after this treatment. We plan to perform comprehensive functional and
      imaging tests to determine significant predictive factors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the present study is to investigate predictive factors of treatment outcome
      after intravitreal injection of Lucentis (Ranibizumab) in eyes with macular edema associated
      with central retinal vein occlusion (CRVO) using various comprehensive clinical tests
      including visual filed, spectral-domain optical coherence tomography (SD-OCT), ultra
      wide-field fluorescein angiography, new flicker electroretinogram (ERG) using skin
      electrodes. Corrected visual acuity, visual filed, spectral-domain optical coherence
      tomography (SD-OCT), ultra wide-field fluorescein angiography, and new flicker
      electroretinogram (ERG) using skin electrodes are performed before and 3, 6, 9, 12 months
      after the treatment.  Predictive factors of treatment outcome are statistically analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Best-corrected visual acuity</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Central Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Intravitreal injection of Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <arm_group_label>Intravitreal injection of Ranibizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Macular edema associated with central retinal vein occlusion

          -  Best corrected visual acuity  &lt; 20/30

          -  Central macular thickness &gt; 300

          -  Period from symptom onset to treatment &lt; 12 months

        Exclusion Criteria:

          -  Any past history of treatment for macular edema (e.g. anti-VEGF injection, steroid,
             vitrectomy)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mineo Kondo, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Mie University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mineo Kondo, MD, PhD</last_name>
    <phone>+81-59-231-5027</phone>
    <email>mineo@clin.medic.mie-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu</city>
        <state>Aichi</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mineo Kondo, MD. PhD.</last_name>
      <phone>+81-59-231-5027</phone>
      <email>mineo@clin.medic.mie-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.medic.mie-u.ac.jp/ophthalmology/</url>
    <description>Department of Ophthalmology, Mie University Graduate School of Medicine</description>
  </link>
  <reference>
    <citation>Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010 Jun;117(6):1124-1133.e1. doi: 10.1016/j.ophtha.2010.02.022. Epub 2010 Apr 9.</citation>
    <PMID>20381871</PMID>
  </reference>
  <reference>
    <citation>Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG. Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology. 2013 May;120(5):1057-63. doi: 10.1016/j.ophtha.2012.11.011. Epub 2013 Feb 14.</citation>
    <PMID>23415775</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>March 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mie University</investigator_affiliation>
    <investigator_full_name>Mineo Kondo</investigator_full_name>
    <investigator_title>MD. PhD.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
